Obermatt

Qiagen

GER:QIA · NL0015002SN0
Life Sciences Tools & ServicesLarge

360

81
EV / EBIT82
Price / Owner Earnings54
Owner Earnings Yield97
Dividend Yield1
Price/Sales67
EV / Gross Profit75
Price/Book61
Return on Capital71
Cash Return on Capital79
Return on Equity76
EBIT Margin87
Gross Profitability69
Cash Conversion43
Accruals46
Owner Earnings Margin81
Sales growth32
Profit Growth86
Long-Term EPS Growth22
Owner Earnings Growth48
Reinvestment21
Price momentum33
Debt load59
Refinancing84
Debt Payback48
Liquidity85
Analyst ratings17
Opinion Changes57
Price Target Upside55
Market mood79
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Qiagen clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryNetherlands
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Websiteqiagen.com
ISINNL0015002SN0
Last UpdateApr 2, 2026
Themes
Health DiagnosticsSoftware DevelopmentOncologyProcess AutomationGeneticsText AnalyticsArtificial IntelligenceBiotechnology

Description

Qiagen N.V. (QIAGEN) is a global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. The company's Sample technologies isolate and process D…

Analysis

Hidden champion

Qiagen N.V. is what we call a hidden champion: a strong business that the market is not pricing as one.

The price is fair. You pay 20.2× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 6% yearly growth; analysts expect 6%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
92
2023202420252026

All-time high

98

Sep 2025

All-time low

20

Jan 2024

Average rank

75

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
28
26
46
Price/Earnings
44
76
74
66
Price/Book
61
70
72
73
Dividend Yield
1
32
1
1
Value (overall)
64
58
41
65

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Qiagen with its peers
Oxford Nanopore Technologies
LSE:ONT
23
CountryUK
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MDxHealth
NAQ:MDXH
43
CountryBelgium
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ChemoMetec
CPH:CHEMM
83
CountryDenmark
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →